Stockscreener 앱 받기
1.82
0.55%
-0.01
Engene Therapeutics Inc 주식(ENGN)의 최신 뉴스
Deep Track Capital Exits enGene Therapeutics (ENGN) Stake in Sec - GuruFocus
enGene Therapeutics Inc. Stock 12‑Month Price Target Cut to $3.43, Implies 102% Upside - TradingView
enGene (NASDAQ:ENGN) Raised to "Sell" at Wall Street Zen - MarketBeat
Perceptive Advisors (NASDAQ: ENGN) discloses 9.99% beneficial stake with warrant cap - Stock Titan
enGene Holdings (ENGN): Venrock investor group reports 0.0% stake and no voting power - Stock Titan
Deep Track exits enGene Therapeutics (ENGN) position, reports 0% ownership - Stock Titan
Raymond Debbane (ENGN) discloses 9.3% enGene stake via Invus and Avicenna - Stock Titan
enGene Eyes 2027 Approval as Detalimogene Targets Expanding Bladder Cancer Market - MarketBeat
Blue Owl Capital Holdings (ENGN) discloses 0.76% warrant-based stake in enGene - Stock Titan
enGene Therapeutics Inc. (S0N0.F) analyst ratings, estimates and forecasts - uk.finance.yahoo.com
enGene highlights detalimogene NMIBC KOL insights and outlook - TipRanks
enGene Therapeutics Inc. (ENGN) Discusses Market Insights and Clinical Development in Non-Muscle Invasive Bladder CancerSlideshow (NASDAQ:ENGN) 2026-08-11 - Seeking Alpha
enGene Therapeutics Inc.Common Stock (ENGN) Stock Price, News, Quote & History - FinancialContent
enGene Holdings Inc (ENGN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
enGene Therapeutics Inc. (S0N0.F) Latest Press Releases & Corporate News - Yahoo! Finance Canada
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
enGene to Host Virtual KOL Event to Discuss Emerging Non-Muscle Invasive Bladder Cancer (NMIBC) Market Insights, on August 11, 2026 - Business Wire
enGene Holdings Inc. (NASDAQ:ENGN) Given Consensus Rating of "Hold" by Analysts - MarketBeat
enGene Therapeutics Inc. Revenue Breakdown – BOATS:ENGNW - TradingView
enGene (NASDAQ:ENGN) Downgraded to "Strong Sell" Rating by Wall Street Zen - MarketBeat
enGene Therapeutics Inc. Revenue Breakdown – NASDAQ:ENGN - TradingView
Siren L.L.C. Has $35.77 Million Stake in enGene Holdings Inc. $ENGN - MarketBeat
Executive options at enGene Therapeutics (ENGN) vesting over 4 years - Stock Titan
enGene Therapeutics (NASDAQ: ENGN) outlines insider RSUs and options - Stock Titan
enGene Therapeutics (ENGN) sees 5.0% beneficial stake reported by Acorn group - Stock Titan
enGene Holdings appoints new chairman to guide growth - The Globe and Mail
enGene Highlights Progress of Lead Bladder Cancer Therapy - TipRanks
enGene Therapeutics (NASDAQ: ENGN) posts 54% response in NMIBC study - Stock Titan
EnGene Therapeutics (ENGN) price target decreased by 64.55% to 8.72 - MSN
enGene Therapeutics announces board changes - The Pharma Letter
enGene names Michael Heffernan board chairman as Richard Glickman steps down - Bitget
enGene Updates Corporate Presentation, Says Pivotal LEGEND 12‑Month Data and BLA Filing Expected 2H 2026 - TradingView
enGene appoints Michael Heffernan as board chairman By Investing.com - Investing.com Australia
enGene appoints Michael Heffernan as board chairman - Investing.com
Dr. Richard Glickman resigns as chairman of enGene Therapeutics - TradingView
enGene Therapeutics (Nasdaq: ENGN) names new chair, plans BLA filing - Stock Titan
enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones - Business Wire
Bronstein, Gewirtz & Grossman, LLC Encourages enGene Therapeutics - The National Law Review
enGene Therapeutics (ENGN) JMP Hematology and Oncology Summit 2024 Summary - Quartr
enGene reports 54% response rate in bladder cancer trial - Investing.com
Piper Sandler downgrades enGene Therapeutics (ENGN) - MSN
enGene Therapeutics Inc. Actuals & Estimates (NASDAQ:ENGN) - TradingView
enGene Therapeutics Inc. Financial Disclosures & Filings - TradingView
Enterprise value to EBITDA forward of enGene Therapeutics Inc. – NASDAQ:ENGN - TradingView
Enterprise value to revenue forward of enGene Therapeutics Inc. – NASDAQ:ENGN - TradingView
ENGNenGene Therapeutics Inc Volatility & Greeks - Finviz
Price to earnings forward of enGene Therapeutics Inc. – NASDAQ:ENGN - TradingView
Enterprise value to EBIT forward of enGene Therapeutics Inc. – NASDAQ:ENGN - TradingView
Price to sales forward of enGene Therapeutics Inc. – NASDAQ:ENGN - TradingView
enGene Therapeutics Inc. Actuals & Estimates (FWB:S0N0) - TradingView
Layoff Tracker: Biogen axes ‘small number’ of Apellis roles after $5.6B buy - BioSpace
ENGN Forecast — Price Target — Prediction for 2027 - TradingView
Number of shareholders of enGene Therapeutics Inc. – NASDAQ:ENGNW - TradingView
A Quick Look at Today's Ratings for EnGene Therapeutics(ENGN.US), With a Forecast Between $2 to $6 - Moomoo
enGene Therapeutics - The Business Journals
Morgan Stanley Downgrades EnGene to Underweight From Equalweight - Moomoo
ENGN Downgraded by Morgan Stanley -- Rating Changed to Underweig - GuruFocus
EnGene Shares Fall After Morgan Stanley Downgrade - Moomoo
enGene Therapeutics (ENGN) lifts restructuring and retention cost estimates - Stock Titan
0.86%
0.31%
자본화:
|
볼륨(24시간):